Exelixis, Inc. - Common Stock (NQ:EXEL)

58.24 -0.15 (-0.26%)

Delayed Quote Updated: 10:35 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

EXEL earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Exelixis: Q3 Earnings Insights ↗

November 02, 2021

Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis...

Via Benzinga

Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 02, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Earnings Perspective: Return On Capital Employed ↗

November 02, 2021

According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18...

Via Benzinga

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

Here's My Top Value Stock To Buy Right Now ↗

November 01, 2021

EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.

Via Talk Markets

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Down 76%: Is Cortexyme Stock a Bargain? ↗

October 28, 2021

The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.

Via The Motley Fool

Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

October 19, 2021

From Exelixis, Inc.

Via Business Wire

EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock ↗

October 18, 2021

Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A...

Via Benzinga

Topics Regulatory Compliance

More Chinese Trouble ↗

October 14, 2021

A day after the consumer price rise there was another price rise for producer markets.

Via Talk Markets

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

October 14, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

October 14, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation ↗

September 20, 2021

The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗

October 07, 2021

Upgrades For State Street Corporation (NYSE:

Via Benzinga

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021

September 20, 2021

From Exelixis, Inc.

Via Business Wire

A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2% ↗

September 20, 2021

Pre-open movers U.S. stock futures traded sharply lower in early pre-market trade after recording losses in the previous session. Investors are awaiting earnings results from...

Via Benzinga

Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021

September 18, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

September 17, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery ↗

September 16, 2021

Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal...

Via Benzinga

Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021

September 16, 2021

From Exelixis, Inc.

Via Business Wire

2 Top Biotech Stocks to Buy Right Now ↗

September 11, 2021

Both have underperformed the market recently. And both are primed for a comeback.

Via The Motley Fool

Exelixis Statement on the Passing of Two Senior Executives

September 06, 2021

From Exelixis, Inc.

Via Business Wire

Is Exelixis Stock a Buy? ↗

September 02, 2021

This biotech stock is down, but it's not out just yet.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

September 01, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer ↗

August 26, 2021

Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...

Via Benzinga

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

August 25, 2021

From Exelixis, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 17, 2021

Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9...

Via Benzinga

Exelixis, Invenra Expand Oncology Pact ↗

August 16, 2021

Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented...

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.